Rosacea, Perioral Dermatitis and Similar Dermatoses, Flushing and Flushing Syndromes

Rook's Textbook of Dermatology: Eighth Edition

Volumn 2, Issue , 2010, Pages 2034-2053

  Berth Jones, John ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Acne agminata; Carcinoid syndrome; Clinical picture of perioral dermatitis being distinctive; Corticosteroid induced rosacea; Idiopathic facial aseptic granuloma; Range of dermatoses presenting facial eruptions and or flushing; Rhinophyma and other phymas; Rosacea, disease lacking entirely satisfactory definition; Rosacea, perioral dermatitis and similar dermatoses, flushing and flushing syndromes; Salivary gland involvement tear secretion associated with ocular rosacea

Indexed keywords

EID: 84888727433     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444317633.ch43     Document Type: Chapter

References (239)

1. Marks R. Rosacea: hopeless hypotheses, marvelous myths and dermal disorganization. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 293-9.
2. Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.
3. Rosen T, Stone MS. Acne rosacea in blacks. J Am Acad Dermatol 1987; 17: 70-3.
4. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol (Stockh) 1989; 69: 419-23.
5. Kyriakis KP, Palamaras I, Terzoudi S et al. Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005; 53: 918-9.
6. Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol 1992; 9: 22-6.
7. Burton JL, Pye RJ, Meyrick G, Shuster S. Sebum excretion rate in rosacea. Br J Dermatol 1975; 92: 541-3.
8. Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol 1994; 130: 359-62.
9. Tan SG, Cunliffe WJ. Rosacea and migraine. Br Med J 1976; i (6000): 21.
10. Guzman-Sanchez DA, Ishiuji Y, Patel T et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol 2007; 57: 800-5.
11. Rosina P, Zamperetti MR, Giovannini A et al. Videocapillaroscopic alterations in erythematotelangiectatic rosacea. J Am Acad Dermatol 2006; 54: 100-4.
12. Smith JR, Lanier VB, Braziel RM et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 2007; 91: 226-9.
13. Oztas MO, Balk M, Ogüs E et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28: 188-92.
14. Baz K, Cimen MY, Kokturk A et al. Plasma reactive oxygen species activity and antioxidant potential levels in rosacea patients: correlation with seropositivity to Helicobacter pylori. Int J Dermatol 2004; 43: 494-7.
15. Yamasaki K, Di Nardo A, Bardan A et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13: 975-80.
16. Anon. Rosacea in hot water. Lancet 1981; i (8221): 647.
17. Guarrera M, Parodi A, Cipriani C et al. Flushing in rosacea: a possible mechanism. Arch Dermatol Res 1982; 272: 311-6.
18. Powell FC, Corbally N, Powell D. Substance P levels in rosacea. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 307-10.
19. Bernstein JE, Soltani K. Alcohol-induced rosacea flushing blocked by naloxone. Br J Dermatol 1982; 107: 59-61.
20. Marks R. Concepts in pathogenesis of rosacea. Br J Dermatol 1968; 80: 170-7.
21. Usher B, Young G. Gastroscopic studies in rosacea. Can Med Assoc J 1956; 75: 111-3.
22. Bonamigo RR, Leite CS, Wagner M, Bakos L. Rosacea and Helicobacter pylori: interference of systemic antibiotic in the study of possible association. J Eur Acad Dermatol Venereol 2000; 14: 424-5.
23. Fry L, Swann JC. Gastrocamera studies in rosacea. Br J Dermatol 1968; 80: 737-9.
24. Watson WC, Paton E, Murray D. Small bowel disease in rosacea. Lancet 1965; ii: 47-50.
25. Powell FC, Dawa MA, Duguid C. Positive Helicobacter pylori serology in rosacea patients. Ir J Med Sci 1992; 161: S75.
26. Rebora A, Drago F, Parodi A. May helicobacter pylori be important for dermatologists? Dermatology 1995; 191: 6-8.
27. Schneider MA, Skinner RBJ, Rosenberg EW et al. Serologic determination of Hp in rosacea patients and controls. Clin Res 1992; 40; 831A.
28. Sharma VK, Lynn A, Kaminski M et al. A study of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea. Am J Gastroenterol 1998; 93: 220-2.
29. Jones MP, Knable AL, White MJ, Durning SJ. Helicobacter pylori in rosacea: lack of an association. Arch Dermatol 1998; 134: 511.
30. Utas S, Ozbakir O, Turasan A, Utas C. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol 1999; 40: 433-5.
31. Erel A, Oztas N, Ilter N et al. Helicobacter pylori seroprevalence in patients with acne rosacea. J Eur Acad Dermatol Venereol 1995; 5 (Suppl. 1): S151.
32. Son SW, Kim IH, Oh CH, Kim JG. The response of rosacea to eradication of Helicobacter pylori. Br J Dermatol 1999; 140: 984-5.
33. Szlachcic A, Sliwowski Z, Karczewska E et al. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol 1999; 50: 777-86.
34. Diaz C, O'Callaghan CJ, Khan A, Ilchyshyn A. Rosacea: a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Derm Venereol 2003; 83: 282-6.
35. Kolibasova K, Tothova I, Baumgartner J, Filo V. Eradication of Helicobacter pylori as the only successful treatment in rosacea. Arch Dermatol 1996; 132: 1393.
36. Mayr-Kanhauser S, Kranke B, Kaddu S, Mullegger RR. Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. Eur J Gastroenterol Hepatol 2001; 13: 1379-83.
37. Bamford JL, Tilden RL, Blankush JL, Gangeness DE. The effect of the treatment of Helicobacter pylori infection on rosacea. Arch Derm 1999; 135: 659-63.
38. Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993; 128: 650-9.
39. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999; 41: 775-7.
40. Jansen T, Kastner U, Kreuter A, Altmeyer P. Rosacea-like demodicosis associated with acquired immunodeficiency syndrome. Br J Dermatol 2001; 144: 139-42.
41. Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow and the role of Demodex folliculorum. J Am Acad Dermatol 1992; 26: 590-3.
42. Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol 1993; 28: 443-8.
43. Georgala S, Katoulis AC, Kylafis GD et al. Increased density of Demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea. J Eur Acad Dermatol Venereol 2001; 15: 441-4.
44. Abd-El-Al AM, Bayoumy AM, Abou Salem EA. A study on Demodex folliculorum in rosacea. J Egypt Soc Parasitol 1997; 27: 183-95.
45. Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol 1998; 37: 421-5.
46. Pena GP, Andrade Filho JS. Is demodex really non-pathogenic? Rev Inst Med Trop Sao Paulo 2000; 42: 171-3.
47. Hoekzema R, Hulsebosch HJ, Bos JD. Demodicosis or rosacea: what did we treat? Br J Dermatol 1995; 133: 294-9.
48. Roth AM. Demodex folliculorum in hair follicles of eyelid skin. Ann Ophthalmol 1979; 11: 37-40.
49. English FP, Nutting WB. Demodicosis of ophthalmic concern. Am J Ophthalmol 1981; 91: 362-72.
50. Ayres S Jr, Mihan R. Rosacea-like demodicosis involving the eyelids. Arch Dermatol 1967; 95: 63-6.
51. Post CF, Juhlin E. Demodex folliculorum and blepharitis. Arch Dermatol 1963; 88: 298-302.
52. Kamoun B, Fourati M, Feki J et al. Blepharitis due to demodex: myth or reality? J Fr Ophthalmol 1999; 22: 525-7.
53. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol 1969; 100: 683-91.
54. Ramelet AA, Perroulaz G. Rosacee: etude histopathologique de 75 cas. Ann Dermatol Venereol 1988; 115: 801-6.
55. Ecker RI, Winkelmann RK. Demodex granuloma. Arch Dermatol 1979; 115: 343-4.
56. Roihu T, Kariniemi A-L. Demodex mites in acne rosacea. J Cutan Pathol 1998; 25: 550-2.
57. Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis 2007; 80: 149-51.
58. Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis 1995; 56: 177-9.
59. Kocak M, Yagli S, Vahapoglu G, Eksioglu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002; 205: 265-70.
60. Forton F, Seys B, Marchal J-L, Song M. Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy. Br J Dermatol 1998; 138: 461-6.
61. Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol 2007; 157: 474-81.
62. Vin-Christian K, Maurer TA, Berger TG. Acne rosacea as a cutaneous manifestation of HIV infection. J Am Acad Dermatol 1994; 30: 139-40.
63. Barrio J, Lecona M, Hernanz JM et al. Rosacea-like demodicosis in an HIVpositive child. Dermatology 1996; 192: 143-5.
64. Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 2004; 50: 266-72.
65. Tan ST, Bialostocki A, Armstrong JR. Pulsed dye laser therapy for rosacea. Br J Plast Surg 2004; 57: 303-10.
66. Berg M, Edström DW. Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea. Lasers Surg Med 2004; 34: 266-8.
67. Marks R, Wilson Jones E. Disseminated rosacea. Br J Dermatol 1969; 81: 16-28.
68. Whitlock FA. Psychosomatic aspects of rosacea. Br J Dermatol 1961; 73: 137-48.
69. Wilkin JK. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol 1981; 76: 15-8.
70. Logan RA, Griffiths WAD. Climatic factors and rosacea. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 311-5.
71. Jansen T, Plewig G. The treatment of rosaceous lymphoedema. Clin Exp Dermatol 1997; 22: 57.
72. Scerri L, Saihan EM. Persistent facial swelling in a patient with rosacea. Arch Dermatol 1995; 131: 1069-74.
73. Bernardini FP, Kersten RC, Khouri LM et al. Chronic eyelid lymphedema and acne rosacea. Report of two cases. Ophthalmology 2000; 107: 2220-3.
74. Michel JL, Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea. Ann Dermatol Venereol 2003; 130: 20-4.
75. Starr PAJ, McDonald R. Oculocutaneous aspects of rosacea. Proc R Soc Med 1969; 62: 9-11.
76. Erzurum SA, Feder RS, Greenwald MJ. Acne rosacea with keratitis in childhood. Arch Ophthalmol 1993; 111: 228-30.
77. Chamaillard M, Mortemousque B, Boralevi F et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 2008; 144: 167-71.
78. Meschig R, Melnik B, Plewig G. Ophthalmic complications of rosacea. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 321-5.
79. Gudmundsen KJ, O'Donnell BF, Powell FC. Schirmer testing for dry eyes in patients with rosacea. J Am Acad Dermatol 1992; 26: 211-4.
80. Nazir SA, Murphy S, Siatkowski RM et al. Ocular rosacea in childhood. Am J Ophthalmol 2004; 137: 138-44.
81. Bamford JT, Gessert CE, Renier CM et al. Childhood stye and adult rosacea. J Am Acad Dermatol 2006; 55: 951-5.
82. Ohata C, Saruban H, Ikegami R. Granulomatous rosacea affecting the lacrimal and salivary glands. Arch Dermatol 2004; 140: 240-2.
83. Helm KF, Menz J, Gibson LE, Dicken CH. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol 1991; 25: 1038-43.
84. Aroni K, Tsagroni E, Lazaris AC, Patsouris E, Agapitos E. Rosacea: a clinicopathological approach. Dermatology 2004; 209: 177-82.
85. Aroni K, Tsagroni E, Kavantzas N et al. A study of the pathogenesis of Rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 2008; 300: 125-31.
86. Lever L, Marks R. Diagnostic discrimination between acne and rosacea. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 317-20.
87. Bell HK, Poston GJ, Vora J, Wilson NJ. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol 2005; 152: 71-5.
88. Knight AK, Vickers CFH. A follow up of tetracycline treated rosacea. Br J Dermatol 1975; 93: 577-80.
89. Irvine C, Marks R. Prognosis and prognostic factors in rosacea. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 331-3.
90. Akpek EK, Merchant A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology 1997; 104: 1863-7.
91. Del Rosso JQ, Webster GF, Jackson M et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56: 791-802.
92. Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971; ii (7733): 1049-52.
93. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976; i (7971): 1211-2.
94. Bakar O, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004; 43: 151-4.
95. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol 2004; 140: 489-90.
96. Jansen T, Melnik B. Plewig G. Gramnegative Follikulitis als Begleit Komplikation bei Rosazea. Aktuel Dermatol 1994; 20: 381-4.
97. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low dose oral isotretinoin in rosacea. Arch Dermatol 1994; 130: 319-24.
98. Hofer T. Continuous 'microdose' isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol 2004; 29: 204-5.
99. Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 301-5.
100. Nielson PG. Treatment of rosacea with 1% metronidazole cream. A doubleblind study. Br J Dermatol 1983; 108: 327-32.
101. Breneman D, Savin R, Van de Pol C et al. Double-blind, randomized, vehiclecontrolled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol 2004; 43: 381-7.
102. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50: 107-8.
103. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005; 4: 147-50.
104. Weissenbacher S, Merkl J, Hildebrandt B et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007: 156: 728-32.
105. Antille C, Saurat JH, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004; 140: 457-60.
106. Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol 2005; 141: 1168.
107. Sanchez J, Somolinos AL, Almodovar PI et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20 mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 2005; 53: 791-7.
108. Bryld LE, Jemec GB. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 2007; 21: 1199-202.
109. Wilkin JK. The effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20: 202-5.
110. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119: 211-4.
111. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-71.
112. Lowe NJ, Behr KL, Fitzpatrick R et al. Flash lamp pumped dye laser for rosaceaassociated telangiectasia and erythema. J Dermatol Surg Oncol 1991; 17: 522-5.
113. Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci 2002; 17: 26-33.
114. Angermeier MC. Treatment of facial vascular lesions with intense pulsed light. J Cutan Laser Ther 1999; 1: 95-100.
115. Scerri L, Saihan EM. Persistent facial swelling in a patient with rosacea. Arch Dermatol 1995; 131: 1069-74.
116. Bernardini FP, Kersten RC, Khouri LM et al. Chronic eyelid lymphedema and acne rosacea. Report of two cases. Ophthalmology 2000; 107: 2220-3.
117. Bechara FG, Jansen T, Losch R et al. Morbihan's disease: treatment with CO2 laser blepharoplasty. J Dermatol 2004; 31: 113-5.
118. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol 1993; 116: 88-92.
119. Bender A, Zapolanski T, Watkins S et al. Tetracycline suppresses ATPγSinduced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol 2008; 17: 752-60.
120. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003; 76: 417-20.
121. Seal DV, Wright P, Ficker L et al. Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea. Br J Ophthalmol 1995; 79: 42-5.
122. Daković Z, Vesić S, Vuković J et al. Ocular rosacea and treatment of symptomatic Helicobacter pylori infection: a case series. Acta Dermatovenerol Alp Panonica Adriat 2007; 16: 83-6.
123. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol 1969; 100: 683-91.
124. Gubisch W. Das Otophym-Eine Raritat. HNO 1983; 31: 56-8.
125. Lutz ME, Otley CC. Rhinophyma and coexisting occult skin cancers. Dermatol Surg 2001; 27: 201-2.
126. Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. In: Marks R, Plewig G, eds. Acne and Related Disorders. London: Martin Dunitz, 1989: 311-5.
127. Plenk HP. Rhinophyma, associated with carcinoma, treated successfully with radiation. Plast Reconstr Surg 1995; 95: 559-62.
128. Leyden JJ, Thew AM, Kligman AM. Steroid rosacea. Arch Dermatol 1974; 110: 619-22.
129. Ljubojeviae S, Basta-Juzbasiae A, Lipozeneiae J. Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment. J Eur Acad Dermatol Venereol 2002; 16: 121-6.
130. Weston WL, Morelli JG. Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med 2000; 154: 62-4.
131. Egan CA, Rallis TM, Meadows KP, Krueger GG. Rosacea induced by beclomethasone dipropionate spray. Int J Dermatol 1999; 38: 133-4.
132. Bernard LA, Cunningham BB, Al-Suwaidan S et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol 2003; 139: 229-31.
133. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001; 44: 995-8.
134. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396-9.
135. Lee DH, Li K, Suh DH. Pimecrolimus 1% cream for the treatment of steroidinduced rosacea: an 8-week split-face clinical trial. Br J Dermatol 2008; 158: 1069-76.
136. Sneddon I. Perioral dermatitis. Br J Dermatol 1972; 87: 430-4.
137. Wilkinson DS. What is perioral dermatitis? Int J Dermatol 1981; 20: 485-6.
138. Velangi SS, Humphreys F, Beveridge GW. Periocular dermatitis associated with the prolonged use of a steroid eye ointment. Clin Exp Dermatol 1998; 23: 297-8.
139. Bradford LG, Montes LF. Perioral dermatitis and Candida albicans. Arch Dermatol 1972; 105: 892-5.
140. Bendl BJ. Perioral dermatitis: etiology and treatment. Cutis 1976; 17: 903-8.
141. Takiwaki H, Tsuda H, Arase S, Takeichi H. Differences between intrafollicular microorganism profiles in perioral and seborrhoeic dermatitis. Clin Exp Dermatol 2003; 28: 531-4.
142. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 2004; 150: 1136-41.
143. Malik R, Quirk CJ. Topical applications and perioral dermatitis. Australas J Dermatol 2000; 41: 34-8.
144. Weber G. Rosacea like dermatitis. Contraindication or intolerance reaction to strong steroids. Br J Dermatol 1972; 86: 253-9.
145. Cotterill JA. Perioral dermatitis. Br J Dermatol 1979; 101: 259-62.
146. Guin JD. Complications of topical hydrocortisone. J Am Acad Dermatol 1981; 4: 417-22.
147. Dubus JC, Marguet C, Deschildre A et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 2001; 56: 944-8.
148. Adams SJ. Perioral dermatitis in renal transplant recipients maintained on corticosteroids and immunosuppressive therapy. Br J Dermatol 1982; 106: 589-92.
149. Marks R, Black MM. Perioral dermatitis. A histopathologic study of 26 cases. Br J Dermatol 1971; 84: 242-7.
150. Ramelet AA, Delacretaz J. Histopathological study of perioral dermatitis. Dermatologica 1981; 163: 361-9.
151. Wilkinson DS, Kirton V, Wilkinson JD. Perioral dermatitis: a 12-year review. Br J Dermatol 1979; 101: 245-57.
152. Macdonald A, Feiwel M. Perioral dermatitis: aetiology and treatment with tetracycline. Br J Dermatol 1972; 87: 315-9.
153. Wells K, Brodell RT. Topical corticosteroid 'addiction'. A cause of perioral dermatitis. Postgrad Med 1993; 93: 225-30.
154. Wilson RG. Topical tetracycline in the treatment of perioral dermatitis. Arch Dermatol 1979; 115: 637.
155. Veien NK, Munkvad JM, Nielsen AO et al. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol 1991; 24: 258-60.
156. Weber K, Thurmayr R, Meisinger A. A topical erythromycin preparation and oral tetracycline for the treatment of perioral dermatitis: a placebo-controlled trial. J Dermatolog Treat 1993; 4: 57-9.
157. Oppel T, Pavicic T, Kamann S et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis-results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007; 21: 1175-80.
158. Schwarz T, Kreiselmaier I, Bieber T et al. A randomized, double-blind, vehiclecontrolled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol 2008; 59: 34-40.
159. Richey DF, Hopson B. Photodynamic therapy for perioral dermatitis. J Drugs Dermatol 2006; 5: 12-6.
160. Jansen T. Perioral dermatitis successfully treated with topical adapalene. J Eur Acad Dermatol Venereol 2002; 16: 175-7.
161. Dekio S, Jidoi J, Imaoka C. Lupus miliaris disseminatus faciei--report of a case in an elderly woman. Clin Exp Dermatol 1991; 16: 295-6.
162. Shitara A. Clinicopathological and immunological studies of lupus miliaris disseminatus faciei. J Dermatol 1982; 9: 383-95.
163. Bedlow AJ, Otter M, Marsden RA. Axillary acne agminata (lupus miliaris disseminatus faciei). Clin Exp Dermatol 1998; 23: 125-8.
164. Skowron F, Causeret AS, Pabion C et al. F.I.GU.R.E.: facial idiopathic granulomas with regressive evolution. Is lupus miliaris disseminatus faciei still an acceptable diagnosis in the third millennium? Dermatology 2000; 201: 287-9.
165. Kumano K, Tani M, Mwata Y. Dapsone in the treatment of miliary lupus of the face. Br J Dermatol 1983; 109: 57-62.
166. Uesugi Y, Aiba S, Usuba M, Tagami H. Oral prednisolone in the treatment of acne agminata. Br J Dermatol 1996; 134: 1098-100.
167. Seukeran DC, Stables GI, Cunliffe WJ, Sheehan-Dare RA. The treatment of acne agminata with clofazimine. Br J Dermatol 1999; 141: 596-7.
168. Williams HC, Ashworth J, Pembroke AC, Breathnach SM. FACE--Afro-Caribbean childhood eruption. Clin Exp Dermatol 1990; 15: 163-6.
169. Gianotti F, Ermacora E, Bennelli MG, Caputo R. Particuliere dermatite peri-orale infantile: observations sur cinq cas. Bull Soc Franc Dermatol Syph 1970; 77: 341.
170. Marten RH, Presbury DGC, Adamson JE, Cardell BS. An unusual papular and acneiform facial eruption in the negro child. Br J Dermatol 1976; 91: 435-8.
171. Frieden IJ, Prose NS, Fletcher V, Turner ML. Granulomatous perioral dermatitis in children. Arch Dermatol 1989; 125: 369-73.
172. Urbatsch AJ, Frieden I, Williams ML et al. Extrafacial and generalized granulomatous periorificial dermatitis. Arch Dermatol 2002; 138: 1354-8.
173. Misago N, Nakafusa J, Narisawa Y. Childhood granulomatous periorificial dermatitis: lupus miliaris disseminatus faciei in children? J Eur Acad Dermatol Venereol 2005; 19: 470-3.
174. Massa MC, Su WPD. Pyoderma faciale: a clinical study of twenty-nine patients. J Am Acad Dermatol 1982; 6: 84-91.
175. Plewig G, Jansen T, Kligman AM. Pyoderma faciale: a review and report of 20 additional cases: is it rosacea? Arch Dermatol 1992; 128: 1611-7.
176. Jensen SL, Holmes R. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy. J Drugs Dermatol 2003; 2: 554-6.
177. Veraldi S, Scarabelli G, Rizzitelli G, Caputo R. Treatment of rosacea fulminans with isotretinoin and topical alclometasone dipropionate. Eur J Dermatol 1996; 6: 94-6.
178. Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol 2001; 15: 465-7.
179. Boralevi F, Léauté-Labrèze C, Lepreux S; Groupe de Recherche Clinique en Dermatologie Pédiatrique. Idiopathic facial aseptic granuloma: a multicentre prospective study of 30 cases. Br J Dermatol 2007; 156: 705-8.
180. Fox RH, Goldsmith P, Kidd DJ. Cutaneous vasomotor control in the human head, neck and upper chest. J Physiol 1962; 161: 298-312.
181. Gonzalez G, Onofrio BM, Kerr FWL. Vasodilator system for the face. J Neurosurg 1975; 42: 696-703.
182. Wilkin JK. Skin changes in the flushing disorders and the carcinoid syndrome. In: Fitzpatrick TB, Eisen AZ, Wolff K et al., eds. Dermatology in General Medicine, 4th edn. New York: McGraw-Hill, 1993: 2131-6.
183. Wilkin JK. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol 1981; 76: 15-8.
184. Drott C, Claes G, Rex L et al. Long-term effects after surgery for hand sweating and facial blushing. Patients are satisfied in spite of troublesome side-effects. Lakartidningen 2001; 98: 1766-72.
185. Lardinois D, Ris HB. Minimally invasive video-endoscopic sympathectomy by use of a transaxillary single port approach. Eur J Cardiothorac Surg 2002; 21: 67-70.
186. Wilkin JK. Flushing reactions: consequences and mechanisms. Ann Intern Med 1981; 95: 468-76.
187. Hardiman PJ, Abel PD, Ginsberg J. Peripheral vascular effects of gonadotrophin releasing hormone agonists in men. J North Am Menopause Soc 1995; 2: 159-61.
188. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000; 343: 1086-94.
189. Fink HA, Mac Donald R, Rutks IR et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Int Med 2002; 162: 1349-60.
190. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 1999; 141: 424-9.
191. Friedrich M, Sterry W, Klein A et al. Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. Acta Derm-Venereol 2001; 81: 429-30.
192. Arthur AB, Klinkhoff A, Teufel A. Nitritoid reactions: case reports, review, and recommendations for management. J Rheumatol 2001; 28: 2209-12.
193. Puri BK, Easton T, Das I et al. The niacin skin flush test in schizophrenia: a replication study. Int J Clin Prac 1997; 55: 368-70.
194. Wolff PH. Ethnic differences in alcohol sensitivity. Science 1972; 175: 449-50.
195. Koivisto T, Kaihovaara P, Salaspuro M. Acetaldehyde induces histamine release from purified rat peritoneal mast cells. Life Sciences 1999; 64: 183-90.
196. Harada S, Agarawal DP, Goedde HW. Aldehyde dehydrogenase deficiency as a cause of facial flushing reaction to alcohol in Japanese. Lancet 1981; ii: 982.
197. Higuchi S, Muramatsu T, Saito M et al. Ethanol patch test for low Km aldehydrogenase deficiency. Lancet 1987; i: 629.
198. Ward RJ, McPherson AJS, Chow C et al. Identification and characterisation of alcohol-induced flushing in Caucasian subjects. Alcohol Alcoholism 1994; 29: 433-8.
199. Truitt EB, Gaynor CR, Mehl DL. Aspirin attenuation of alcohol-induced flushing and intoxication in Oriental and Occidental subjects. Alcohol 1987; Suppl. 1: 595-9.
200. Miller NS, Goodwin DW, Jones FC et al. Histamine receptor antagonism of intolerance to alcohol in the Oriental population. J Nerv Mental Dis 1987; 175: 661-7.
201. Wiles PG, Pyke DA. The chlorpropamide alcohol flush. Clin Sci 1984; 67: 375-81.
202. Barnett AH, Spiliopoulos AJ, Pyke DA. Blockade of chlorpropamide alcohol flushing by indomethacin suggests an association between prostaglandin and diabetic vascular complications. Lancet 1980; ii: 164-6.
203. Kwok RHA. Chinese restaurant syndrome. N Engl J Med 1968; 278: 796.
204. Ghadimi H, Kumar S, Abaci F. Studies on monosodium glutamate ingestion. Biochem Med 1971; 5: 447-56.
205. Wilkin JK. Does monosodium glutamate cause flushing (or merely 'glutamania'). J Am Acad Dermatol 1986; 15: 225-30.
206. Rosenblum I, Bradley JD, Coulston F. Single- and double-blind studies with oral monosodium glutamate in man. Toxicol Appl Pharmacol 1971; 18: 367-73.
207. Kim R. Flushing syndrome due to Mahimahi (scombroid fish) poisoning. Arch Dermatol 1979; 115: 963-5.
208. Morrow JD, Margolies GR, Rowland J, Roberts LJ. Evidence that histamine is the causative toxin of scombroid fish poisoning. N Engl J Med 1991; 324: 716-20.
209. Cunliffe WJ, Black MM, Hall R et al. A calcitonin secreting thyroid carcinoma. Lancet 1968; ii: 63-6.
210. Murray JS, Paton RR, Pope CE. Pancreatic tumor associated with flushing and diarrhea. N Engl J Med 1961; 264: 436-9.
211. Gulledge AD, Kavanaugh GJ, Priestley JT. Cutaneous flushing as a primary manifestation of functioning insulinoma. Report of a case. Mayo Clin Proc 1967; 42: 547-50.
212. Myers BM, Miralles GD, Taylor CA et al. POEMS syndrome with idiopathic flushing mimicking carcinoid syndrome. Am J Med 1991; 90: 646-8.
213. Oberndorfer S. Karzinoid Tumoren des Dünndarms. Frankf Z Pathol 1907; 1: 426-9.
214. Memon MA, Nelson H. Gastrointestinal carcinoid tumours: current management strategies. Dis Colon Rectum 1997; 40: 1101-18.
215. Vinik AI, McLeod MK, Fig LM et al. Clinical features, diagnosis and localisation of carcinoid tumours and their management. Gastro Clin N Am 1989; 18: 865-96.
216. Wereide K, Neset G. Skin manifestations in carcinoid syndrome. Acta Derm Venereol (Stockh) 1961; 41: 264-76.
217. Oates JA, Sjoredsma A. A unique syndrome associated with secretion of 5- hydroxytryptophan by metastatic gastric carcinoids. Am J Med 1962; 32: 333-42.
218. Melmon KL, Sjoerdsma A, Mason DT. Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumours. Am J Med 1965; 39: 568-81.
219. Creutzfeldt W, Stockmann F. Carcinoids and carcinoid syndrome. Am J Med 1987; 82 (Suppl. 5B): 4-16.
220. Grahame-Smith DG. The carcinoid syndrome. Am J Cardiol 1968; 21: 376-87.
221. Smith AG, Greaves MW. Blood prostaglandin activity associated with noradrenaline- provoked flush in the carcinoid syndrome. Br J Dermatol 1974; 90: 547-51.
222. Fries JF, Lindgren JA, Bull JM. Scleroderma-like lesions and the carcinoid syndrome. Arch Intern Med 1973; 131: 550-3.
223. Lee SS, Biro H, Price E. Pyoderma gangrenosum with carcinoid tumours. Cutis 1976; 18: 791-4.
224. Creamer JD, Whittaker SJ, Griffiths WAD. Multiple endocrine neoplasia type I presenting as rosacea. Clin Exp Dermatol 1996; 21: 170-1.
225. Bell HK, Poston GJ, Vora J, Wilson NJ. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol 2005; 152: 71-5.
226. Adamson AR, Grahame-Smith DG, Peart WS, Starr M. Pharmacological blockade of carcinoid flushing provoked by catecholamines and alcohol. Lancet 1969; ii: 293-7.
227. Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-9.
228. Duh QY, Hybarger CP, Geist R et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg 1987; 154: 142-8.
229. Norheim I, Oberg K, Theodorsson-Norheime E et al. Malignant carcinoid tumours. An analysis of 103 patients in relation to tumour localization, hormone production and survival. Ann Surg 1987; 206: 115-26.
230. Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with carcinoid syndrome. N Engl J Med 1967; 277: 1103-8.
231. Wilkin JK, Rountree CB. Blockade of carcinoid flush with cimetidine and clonidine. Arch Dermatol 1982; 118: 109-11.
232. Metz SA, Halter JB, Porte D et al. Suppression of plasma catecholamines and flushing by clonidine in man. J Clin Endocrinol Metab 1978; 46: 83-90.
233. Granerus G, Ahlman H. Histamine metabolism in patients with foregut carcinoid tumours. Agents Actions 1993; 38: C165-8.
234. Grahame-Smith DG. The carcinoid syndrome. Am J Cardiol 1968; 21: 376-87.
235. Camisa C. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology. Arch Dermatol 1989; 125: 407-12.
236. Tomassetti P, Migliori M, Caletti GC et al. Treatment of type II gastric carcinoid tumours with somatostatin analogues. N Engl J Med 2000; 343: 551-4.
237. Maton PN, Camilleri M, Griffin G et al. Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J 1983; 287: 932-5.
238. Marsh HM, Martin JK Jr, Kvols LK et al. Carcinoid crisis during anaesthesia: a successful treatment with a somatostatin analogue. Anesthesiology 1987; 66: 89-91.
239. Oberg K, Norheim I, Lind E. Treatment of malignant carcinoid tumours with human leukocyte interferon: long term results. Cancer Treat Rep 1986; 70: 1297-304.